ADCT announced results from the ongoing pivotal Phase 2 trial of camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma. An ORR of 70.1% and CR rate of 33.3% was observed with a median DOR of 13.7 months for all responders in patients who were refractory or had relapsed after a median of 6 prior treatments, including brentuximab vedotin and a PD-1 blockade.
Immunogen announced a multi-year collaboration to research novel ADCs with Oxford Bio, utilizing ImmunoGen's linker-payload technology directed to novel targets identified via Oxford Bio’s proprietary OGAP discovery platform.
The short interest of Mersana increased in June by 29 % to 6,005,879 on June 15, compared to 4,642,250 on May 13.
Merck & Co. is reportedly mulling buying Seagen, Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen’s market cap of roughly $30 billion. Separately, Seagen presented interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy, with a confirmed ORR of 41% and median DOR that was not reached within almost 19 months of median follow up.
Alkermes presented data from the ARTISTRY-1 trial for nemvaleukin alfa, the company's engineered IL-2 variant immunotherapy, during ASCO meeting. The trial provided important data that has revealed nemvaleukin's PK and PD profile, exhibited similar monotherapy anti-tumor activity as seen with high-dose IL-2, demonstrated anti-tumor activity in combination with Keytruda, and established a differentiated safety and tolerability profile.
ImmunityBio presented at ASCO new positive data from the pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer in situ (QUILT 3032). Total 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median duration of 26.6 months.
The short interest of Nektar decreased in June by 3 % to 17,639,776 on June 15, compared to 18,096,700 on May 13.
Xencor reported at ASCO initial dose-escalation data from Phase 1 study evaluating XmAb104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). XmAb104 has been well tolerated and is exhibiting a distinct safety profile compared to other clinical ICOS programs.
Allogene announced that FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-501A in relapsed or refractory LBCL. The RMAT designation was based on the potential of ALLO-501A to address the unmet need for patients who have failed other therapies.
Autolus presented at EHA congress clinical data across multiple programs. AUTO4 showed high level of clinical activity with a novel targeting approach for patients with T-cell lymphoma. AUTO1/22 demonstrated encouraging and durable responses in children ineligible for commercial CAR T product. Obe-cel showed high level of sustained clinical activity in B-NHL patients and first activity in primary CNS lymphoma.
The short interest of Bellicum decreased in June by 9 % to 161,687 on June 15, compared to 178,355 on May 13.
Mustang announced updated interim data from the ongoing Phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy. The results showed 94% ORR and 78% CR rate in patients with follicular lymphoma, including complete response in a patient previously treated with CD19-targeted CAR T therapy, and 100% ORR in other B-cell NHL.
Arcus participated in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference.
Immutep presented new data from first line NSCLC patients of the Phase 2 TACTI-002 trial evaluating eftilagimod alpha in combination with Keytruda in 114 patients. The combination improved ORR by local read of 38.6% (intent to treat, 44/114 patients) and 42.7% (evaluable patients, 44/103).
Clovis announced initial LuMIERE Phase 1 data demonstrating a manageable safety profile with preliminary evidence of activity from nine patients. FAP-2286 has shown high tumor uptake and prolonged retention across a range of solid tumors.